jetcityimage/iStock Editorial via Getty Images
Eli Lilly (NYSE:LLY) and Organon (NYSE:OGN) have expanded their commercialization deal for migraine medicine Emgality (galcanezumab) in 11 additional markets.
Organon will serve as the sole distributor and promoter for Emgality in Canada, Colombia, Israel, South Korea, Kuwait, Mexico, Qatar, Saudi Arabia, Taiwan, Turkey and the UAE.